Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

Home
/
insight
/
details

Understanding PD-L1 Test and its Role in Cancer Immunotherapy

NextEdge Admin

05 May 2024

3 min 2 sec

IHC,Precision medicine,diagnostic,biomarker

The PD-L1 test holds significant importance in personalized cancer treatment by evaluating tumor tissue to detect the presence and quantity of the PD-L1 protein. This protein plays a pivotal role in immune regulation, inhibiting the body’s immune response by preventing T cells from targeting healthy cells. However, cancer cells with high levels of PD-L1 can exploit this mechanism to evade immune detection and destruction.

Immunotherapy medications, particularly immune checkpoint inhibitors, block the PD-L1 protein, enabling T cells to recognize and destroy cancer cells effectively. Therefore, the PD-L1 test acts as a predictive biomarker, helping clinicians identify patients likely to benefit from immunotherapy.

These immunotherapies disrupt signals from immune checkpoint proteins like PD-L1, enhancing the immune system’s ability to attack tumors. Several PD-L1 inhibitors, such as atezolizumab, durvalumab, nivolumab, and pembrolizumab, have gained FDA approval for various clinical indications and are under evaluation for different malignancies.

The FDA categorizes PD-L1 immunohistochemistry (IHC) tests into companion diagnostic tests and complementary or codiagnostic tests. Companion diagnostic tests are essential for the safe and effective use of a drug, while complementary tests aid in treatment selection but are not obligatory for drug use.

The test is especially relevant for cancers like non-small cell lung cancer, melanoma, and bladder cancer, where immunotherapy has shown promise. It involves obtaining a tumor tissue sample during surgery or biopsy, the method of which varies based on cancer type and location.

Interpreting PD-L1 test results involves assessing whether the tumor has sufficient PD-L1 levels for immunotherapy effectiveness. A positive result suggests potential immunotherapy benefits, while a negative result prompts exploration of alternative treatments. Additional tests may be conducted to further inform treatment decisions.

PD-L1 test is a critical component of personalized cancer care, guiding treatment approaches by identifying patients likely to respond favorably to immunotherapy based on PD-L1 expression levels in their tumors.